Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of Protagonist Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $20.00, for a total value of $17,500.00. Following the completion of the transaction, the insider now owns 4,697 shares in the company, valued at approximately $93,940. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
David Y. Liu also recently made the following trade(s):
- On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $118,790.00.
Shares of Protagonist Therapeutics Inc (NASDAQ PTGX) traded down $0.25 on Monday, reaching $19.25. The company’s stock had a trading volume of 95,800 shares, compared to its average volume of 84,137. Protagonist Therapeutics Inc has a 52-week low of $8.00 and a 52-week high of $26.36.
Large investors have recently made changes to their positions in the company. FMR LLC increased its position in Protagonist Therapeutics by 0.4% in the 2nd quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after buying an additional 10,264 shares in the last quarter. Vanguard Group Inc. increased its position in Protagonist Therapeutics by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares in the last quarter. Senzar Asset Management LLC bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at about $3,094,000. State Street Corp increased its position in Protagonist Therapeutics by 20.9% in the 2nd quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after buying an additional 19,411 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Protagonist Therapeutics by 1.9% in the 1st quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock valued at $1,296,000 after buying an additional 1,850 shares in the last quarter. 39.68% of the stock is currently owned by institutional investors.
PTGX has been the topic of several recent analyst reports. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 18th. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Finally, BMO Capital Markets reduced their price objective on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 19th.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.